BioSpace News Archive

Cognition Therapeutics, Inc. today announced that the Company will release financial results for the fourth quarter and full year ended December 31, 2021 on Wednesday, March 30, 2022.

Sigyn Therapeutics, Inc. announced that it has filed its annual report on Form 10-K for the year ended December 31, 2021 with the Securities and Exchange Commission and provided a corporate update.

Kintara Therapeutics, Inc. today announces that President and CEO Robert Hoffman will participate at the Maxim Group 2022 Virtual Growth Conference, which is being held on March 28-30, 2022.

Smith+Nephew, the global medical technology business, announces it will it showcase its latest innovations for Orthopaedic Reconstruction and Robotics during the American Academy of Orthopaedic Surgeons 2022 Annual Meeting being held in Chicago, IL.

The Company is also participating in the 21st Annual Needham Virtual Healthcare Conference, taking place April 11-14, 2022.

Goldfinch Bio today announced that it will host a virtual event to discuss the unmet need in focal segmental glomerular sclerosis (FSGS), as well as the recently announced clinical data from TRACTION-2, the ongoing Phase 2 trial evaluating GFB-887 as a precision medicine for the treatment of FSGS. GFB-887 is a podocyte-targeting, small molecule inhibitor of Transient Receptor Potential Canonical Channel 5 (TRPC5).

Pharvaris (Nasdaq: PHVS), has published pharmacological data for the novel small molecule bradykinin (BK) B2-receptor antagonist PHA121 (PHA-022121) and its active metabolite PHA-022484, in a recent open-access article in International Immunopharmacology and will be published in the April 2022 issue of the journal.

AM-Pharma’s purpose is to save and improve the lives of patients confronted with severe medical conditions.

LIXTE Biotechnology Holdings, Inc., notes findings by a team of physician-scientists led by principal investigator Dr. Amir Jazaeri, professor of Gynecologic Oncology and Reproductive Medicine at The University of Texas MD Anderson Cancer Center, and reported at the annual meeting of SGO, that a subset of patients with OCCC treated with immune checkpoint inhibitors lived significantly longer than most patients with the same disease treated with the same regimens.

Sharps Compliance Corp., a leading full-service national provider of comprehensive waste management solutions including medical, pharmaceutical and hazardous, announced that it has entered into a new $36.0 million credit facility with a commercial bank.